Shares of NASDAQ:TXG opened at $10.34 on Friday. The stock has a market capitalization of $1.26 billion, a P/E ratio of -6.80 and a beta of 1.93. 10x Genomics has a 1-year low of $9.27 and a 1 ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022, alleging that Vizgen unlawfully used ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

10x Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

European Patent Office grants new CRISPR/Cas9 patent (EP ... providing security to over 150 ERS Genomics licensees. "We also look forward to the forthcoming decision on CRISPR patent Interference ...

European Patent Office grants new CRISPR/Cas9 patent (EP 4 289 948 ... providing security to over 150 ERS Genomics licensees. "We also look forward to the forthcoming decision on CRISPR patent ...